Last reviewed · How we verify
NCT06200493: OPM
Effects of Maximum Strength and Acceleration Ability on Performance and Training in Wheelchair Sports
trial in Spinal Cord Injuries in 10 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | Swiss Paraplegic Research, Nottwil |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 20 September 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Switzerland |
Conditions studied
- Spinal Cord Injuries — all drugs for Spinal Cord Injuries →
- Athletes — all drugs for Athletes →
- Wheelchair — all drugs for Wheelchair →
Sponsor
Swiss Paraplegic Research, Nottwil — full company profile →
Who can join
18 and older, any sex, with Spinal Cord Injuries or Athletes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about the relation between grip position and maximal strength and power in wheelchair rugby and basketball athletes. The main question is to investigate the relationship between maximal isometric force, acceleration, and sprint time. Participants will * pull in their sport wheelchair against a force transducer * push in their sport wheelchair from a force transducer * accelerate as fast as possible with one push * accelerate as fast as possible over a distance of 20m Researchers will compare the wheelchair basketball against wheelchair rugby players to see if there is a difference in the parameters.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06200493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spinal Cord Injuries
Currently open trials in the same condition.
- NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury · NA · recruiting
- NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial · NA · recruiting
- NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury · NA · recruiting
- NCT07488793 — Remote Ischemic Conditioning for PwSCI · NA · recruiting
- NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting
Other Swiss Paraplegic Research, Nottwil trials
Trials by the same sponsor.
- NCT07456722 — Cardiac Morphology and Function in Individuals With Autonomic Dysreflexia · not yet recruiting
- NCT06905470 — The Effects of Eccentric Compared to Standard Strength Training in Primary Spinal Cord Injury Rehabilitation · NA · not yet recruiting
- NCT07165353 — Virtual Walking to Reduce Chronic Neuropathic Pain in Subjects With SCI · NA · recruiting
- NCT06892080 — Urine Incontinence Occurrence and Sexual Hormones in Women With Chronic Spinal Cord Injury/Disease - a Pilot Study · recruiting
- NCT06633588 — Decolonization Efficacy of Polyhexanide vs. Mupirocin · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06200493 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Swiss Paraplegic Research, Nottwil
- Last refreshed: 6 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06200493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing